Charles Simone

Professor and Chief Medical Officer

Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Charles Simone is a Professor and Chief Medical Officer at the New York Proton Center in the United States. His research focuses on radiotherapy advancements, particularly in the treatment of malignancies such as lung cancer and prostate cancer. He has contributed to various articles examining topics such as the integration of immunotherapy, the application of artificial intelligence in cancer assessment, and the impact of proton therapy on treatment side effects.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Bragg peak FLASH radiotherapy (RT) uses a distal tracking method to eliminate exit doses and can achieve superior OAR sparing. This study explores the application of this novel method in stereotactic body radiotherapy prostate FLASH-RT. An in-house platform was developed to enable intensity-modulated proton therapy (IMPT) planning using a single-energy Bragg peak distal tracking method. The patients involved in the study were previously treated with proton stereotactic body radiotherapy (SBRT) using the pencil beam scanning (PBS) technique to 40 Gy in five fractions. FLASH plans were optimized using a four-beam arrangement to generate a dose distribution similar to the conventional opposing beams. All of the beams had a small angle of two degrees from the lateral direction to increase the dosimetry quality. Dose metrics were compared between the conventional PBS and the Bragg peak FLASH plans. The dose rate histogram (DRVH) and FLASH metrics of 40 Gy/s coverage (V40Gy/s) were investigated for the Bragg peak plans. There was no significant difference between the clinical and Bragg peak plans in rectum, bladder, femur heads, large bowel, and penile bulb dose metrics, except for Dmax. For the CTV, the FLASH plans resulted in a higher Dmax than the clinical plans (116.9% vs. 103.3%). For the rectum, the V40Gy/s reached 94% and 93% for 1 Gy dose thresholds in composite and single-field evaluations, respectively. Additionally, the FLASH ratio reached close to 100% after the application of the 5 Gy threshold in composite dose rate assessment. In conclusion, the Bragg peak distal tracking method can yield comparable plan quality in most OARs while preserving sufficient FLASH dose rate coverage, demonstrating that the ultra-high dose technique can be applied in prostate FLASH SBRT.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Liyong Lin

Adjunct Associate Professor

Georgia Institute of Technology

UNITED STATES
View details

Jenghwa Chang

Hofstra University

UNITED STATES
View details

Andrea Riccardo Filippi

Full Professor

University of Pavia

ITALY
View details

Michael Lock

Western University

CANADA
View details

Minglei Kang

Associate Professor, Director of Proton Physics

University of Wisconsin-Madison

UNITED STATES
View details

Dale Lovelock

Mount Sinai Hospital

UNITED STATES
View details

Ying Xiao

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Chin-Cheng Chen

Chief Clinical Physicis

St. Jude Children's Research Hospital

UNITED STATES
View details

Robert Griffin

University of Arkansas for Medical Sciences

UNITED STATES
View details

Wei Liu

Professor

Mayo Clinic Arizona

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.